---
category: news
title: "BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms"
excerpt: "BioXcel Therapeutics, Inc. (\"BTI\" or \"Company\") (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology,"
publishedDateTime: 2020-06-11T11:00:00Z
webUrl: "https://www.benzinga.com/pressreleases/20/06/g16230413/bioxcel-therapeutics-announces-first-patient-enrolled-in-phase-1b2-release-trial-of-bxcl501-for-th"
ampWebUrl: "https://amp.benzinga.com/amp/content/16230413"
cdnAmpWebUrl: "https://amp-benzinga-com.cdn.ampproject.org/c/s/amp.benzinga.com/amp/content/16230413"
type: article
quality: 0
heat: 0
published: false

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

secured: "Usm4Pl/mICMHDm4lolB4Oqflr1EAJP4qZ1pOk/o5glx4JxzQ5/oEO2S3fqYG1qDqTnLrEwBuOll6IwuHHbbHbPANhtzntK5xUZeQrUr/8gwLR48BllJEexe8l0pJkf+Pv4Iz/Vnm0pLlMJB+SjbLty+GxjLmyLJ102cCSukEX/gYTC31nmwUbilHEudxsin0MjpcaIBe4GR3XkMmNfwrihYO2+HLgZjvH0OnkCAQlnaa/x7ls6UZ3lTewNOnCHYr8w7WMu+e7QzBGcHr5a5DOqw8i6is+El09pHTVVcaCnBcJU+kADZD1V1RRPN1Ltqs;5bsAxtJUARfZdyE4t7k2eQ=="
---

